Home › Compare › JSPCF vs ABBV
JSPCF yields 3.64% · ABBV yields 3.06%● Live data
📍 JSPCF pulled ahead of the other in Year 4
Combined, JSPCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JSPCF + ABBV for your $10,000?
JSP Corporation manufactures and sells expanded polymers worldwide. The company offers materials products, such as ARPRO, an impact energy management material that is used in automotive applications, multi-use transport packaging, HVAC housings, and others; STYRODIA for use in various applications comprising packaging for consumer electronics, hot and cold food containers, construction insulation, and within civil engineering materials; and FOAMCORE that is used in prefabricated bathrooms and automotive components. It also provides sheet and board products under the MIRAMAT, CAPLON, P-BOARD, STYRENE PAPER, MIRABOARD, and MIRAFOAM names for advertising boards, construction, food packaging, and industrial packaging markets. The company was incorporated in 1962 and is headquartered in Tokyo, Japan. JSP Corporation is a subsidiary of Mitsubishi Gas Chemical Company, Inc.
Full JSPCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.